Candice Roth, MSN, RN, CENP, Describes the Evolution of Electronic Treatment Pathways at Levine Cancer Institute

Video

Candice Roth, MSN, RN, CENP, spoke about how the electronic treatment pathways have evolved over time.

At the Association of Community Cancer Centers 48th Annual Meeting and Cancer Center Business Summit, CancerNetwork® spoke with Candice Roth, MSN, RN, CENP, assistant vice president at Levine Cancer Institute in Charlotte, North Carolina, about how measuring success of electronic treatment pathways has evolved from counting the number of clicks to specifically pinpointing how clinicians are using the platform.

Transcript:

First and foremost, it was a new platform several years ago, so just getting providers to use it compared with the way they previously practiced [was difficult]. It was [simply about] just counting the number of clicks initially in terms of metrics. [We were focused on making] sure that our providers were aware that they needed to use this platform and or that it was available for their use. Similarly, any of our nurses can do the same.

In terms of metrics, initially it was very much about how many clicks we had. Then as we progressed, we’ve been able to track clinical trial touchpoint eligibility for patients. We also look at ensuring that we are being consistent and standard by way of how we treat breast cancer, for example. We have all those metrics and all of the behind the scenes [information] that we monitor and present by way of dashboards to all of our providers.

Recent Videos
According to Megan Mullins, PhD, MPH, challenging cultural norms surrounding death and dying may reduce the receipt of low-value end-of-life cancer care.
Earlier and more frequent talks about disabling ICDs with patients receiving end-of-life care and their families may help avoid excessive pain.
Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.
AI-powered tools may help alleviate doctor burnout and give clinicians more time to directly engage with patients.
Artificial intelligence may have the potential to enrich pathology practices to help identify aspects of tumor biology not seen with the human eye.
Efficacy results from the MASAI trial preceded the creation of the UK-funded EDITH trial, assessing 5 AI platforms in 700,000 women undergoing mammography.
In considering patients’ busy lives, AI may help reduce the number of visits required to fully stage and grade cancers.
Related Content